We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ionis Pharmaceuticals Inc (IONS) Common Stock USD0.001

Sell:$36.13 Buy:$36.29 Change: $0.01 (0.03%)
NASDAQ:2.10%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$36.13
Buy:$36.29
Change: $0.01 (0.03%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$36.13
Buy:$36.29
Change: $0.01 (0.03%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Contact details

Address:
2855 Gazelle Court
CARLSBAD
92010
United States
Telephone:
+1 (760) 9319200
Website:
https://www.ionis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IONS
ISIN:
US4622221004
Market cap:
$5.77 billion
Shares in issue:
157.90 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Brett Monia
    Chief Executive Officer, Director
  • Elizabeth Hougen
    Chief Financial Officer, Executive Vice President - Finance
  • C. Frank Bennett
    Executive Vice President, Chief Scientific Officer
  • Joseph Baroldi
    Executive Vice President, Chief Business Officer
  • Richard Geary
    Executive Vice President, Chief Development Officer
  • Kyle Jenne
    Executive Vice President - commercial
  • Eugene Schneider
    Executive Vice President, Chief Clinical Development and Operations Officer
  • Eric Swayze
    Executive Vice President - Research
  • Patrick O'Neil
    Chief Legal Officer, General Counsel and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.